Laborie Medical Technologies, a diagnostic and therapeutic medical technology company, agreed to lead a $20m Series C round in Urotronic, a Minnesota-based medical device company, along with current shareholders. "We are excited to have LABORIE invest in our company and become a global distribution partner to commercialize our disruptive technologies. Optilume™ offers physicians a device that has the potential to lift the burdens of current treatments. The investment by LABORIE, a leader in urology care globally, strengthens Optilume's position as a cutting-edge product in the urology device market," David Perry, Urotronic President and CEO.